1325 related articles for article (PubMed ID: 8940515)
1. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs].
Abu-Abid S; Gutman M; Lev D; Inbar M; Chaitchik S; Sorkine P; Rudick V; Meller I; Klausner JM
Harefuah; 1996 Oct; 131(7-8):227-32, 296, 295. PubMed ID: 8940515
[TBL] [Abstract][Full Text] [Related]
2. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
[TBL] [Abstract][Full Text] [Related]
3. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity.
Bickels J; Manusama ER; Gutman M; Eggermont AM; Kollender Y; Abu-Abid S; Van Geel AN; Lev-Shlush D; Klausner JM; Meller I
Eur J Surg Oncol; 1999 Oct; 25(5):509-14. PubMed ID: 10527599
[TBL] [Abstract][Full Text] [Related]
4. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
6. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
[TBL] [Abstract][Full Text] [Related]
7. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
8. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
[TBL] [Abstract][Full Text] [Related]
9. TNF dose reduction in isolated limb perfusion.
Grünhagen DJ; de Wilt JH; van Geel AN; Graveland WJ; Verhoef C; Eggermont AM
Eur J Surg Oncol; 2005 Nov; 31(9):1011-9. PubMed ID: 16099618
[TBL] [Abstract][Full Text] [Related]
10. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
[TBL] [Abstract][Full Text] [Related]
12. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
[TBL] [Abstract][Full Text] [Related]
13. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
14. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
Kettelhack C; Hohenberger P; Schlag PM
Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
[TBL] [Abstract][Full Text] [Related]
15. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
16. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
17. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
Grünhagen DJ; de Wilt JH; Verhoef C; van Geel AN; Eggermont AM
Eur J Surg Oncol; 2005 Oct; 31(8):912-6. PubMed ID: 16098709
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient.
Bonvalot S; Rimareix F; Causeret S; Le Péchoux C; Boulet B; Terrier P; Le Cesne A; Muret J
Ann Surg Oncol; 2009 Dec; 16(12):3350-7. PubMed ID: 19830495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
